GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Cyclically Adjusted Book per Share

Zydus Lifesciences (BOM:532321) Cyclically Adjusted Book per Share : ₹128.88 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Zydus Lifesciences's adjusted book value per share for the three months ended in Mar. 2024 was ₹197.067. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹128.88 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Zydus Lifesciences's average Cyclically Adjusted Book Growth Rate was 16.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 18.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Zydus Lifesciences was 22.20% per year. The lowest was 18.80% per year. And the median was 20.50% per year.

As of today (2024-05-28), Zydus Lifesciences's current stock price is ₹1058.55. Zydus Lifesciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was ₹128.88. Zydus Lifesciences's Cyclically Adjusted PB Ratio of today is 8.21.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Zydus Lifesciences was 8.65. The lowest was 3.61. And the median was 5.30.


Zydus Lifesciences Cyclically Adjusted Book per Share Historical Data

The historical data trend for Zydus Lifesciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Cyclically Adjusted Book per Share Chart

Zydus Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60.58 76.89 93.02 110.45 128.88

Zydus Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 110.45 - 120.61 - 128.88

Competitive Comparison of Zydus Lifesciences's Cyclically Adjusted Book per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zydus Lifesciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's Cyclically Adjusted PB Ratio falls into.



Zydus Lifesciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zydus Lifesciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=197.067/153.0345*153.0345
=197.067

Current CPI (Mar. 2024) = 153.0345.

Zydus Lifesciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 94.103 0.000
201409 38.242 96.780 60.470
201412 0.000 96.780 0.000
201503 44.160 97.163 69.553
201506 0.000 99.841 0.000
201509 48.524 101.753 72.979
201512 0.000 102.901 0.000
201603 55.670 102.518 83.102
201606 0.000 105.961 0.000
201609 62.647 105.961 90.478
201612 0.000 105.196 0.000
201703 67.986 105.196 98.903
201706 0.000 107.109 0.000
201709 74.402 109.021 104.439
201712 0.000 109.404 0.000
201803 85.417 109.786 119.065
201806 0.000 111.317 0.000
201809 87.027 115.142 115.667
201812 0.000 115.142 0.000
201903 101.454 118.202 131.351
201906 0.000 120.880 0.000
201909 100.601 123.175 124.988
201912 0.000 126.235 0.000
202003 101.351 124.705 124.375
202006 0.000 127.000 0.000
202009 114.820 130.118 135.042
202012 0.000 130.889 0.000
202103 126.910 131.771 147.390
202106 0.000 134.084 0.000
202109 158.129 135.847 178.136
202112 0.000 138.161 0.000
202203 166.054 138.822 183.055
202206 0.000 142.347 0.000
202209 164.641 144.661 174.171
202212 0.000 145.763 0.000
202303 173.047 146.865 180.317
202306 0.000 150.280 0.000
202309 185.070 151.492 186.954
202312 0.000 152.924 0.000
202403 197.067 153.035 197.067

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Zydus Lifesciences  (BOM:532321) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Zydus Lifesciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1058.55/128.88
=8.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Zydus Lifesciences was 8.65. The lowest was 3.61. And the median was 5.30.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Zydus Lifesciences Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zydus Lifesciences (BOM:532321) Business Description

Traded in Other Exchanges
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines